Active Ingredient History

  • Now
Setrobuvir was an experimental drug candidate for the treatment of hepatitis C that was discovered at Anadys Pharmaceuticals, which was acquired by Roche in 2011; Roche terminated development in July 2015. It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1.   Wikipedia

  • SMILES: CS(=O)(=O)Nc1ccc2NC(=NS(=O)(=O)c2c1)C3=C(O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4N(Cc6ccc(F)cc6)C3=O
  • Mol. Mass: 560.63
  • ALogP: 2.98
  • ChEMBL Molecule:
More Chemistry
ana598 | ana-598 | setrobuvir


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue